Long‐term results of the combination of the N7 induction chemotherapy and the busulfan‐melphalan high dose chemotherapy
- 23 August 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (6) , 977-981
Abstract
Background: To evaluate long‐term survival of the first cohort of stage‐4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of the primary tumor and high‐dose chemotherapy (HDC) containing Busulfan–Melphalan (Bu‐Mel) followed by autologous stem cell transplantation (ASCT).Procedure: From 1998 to 1999, 47 children were included in the NB97 trial and treated with induction chemotherapy according to the N7 protocol, followed by surgery of the primary tumor. HDC (Busulfan, 600 mg/m2 Melphalan, 140 mg/m2) was administered in patients with partial response of metastases with no more than 3 mIBG spots. Radiotherapy was delivered to the primary tumor site when tumors displayed MYCN amplification.Results: Thirty‐nine patients received Bu‐Mel (83%): 23 who had achieved complete response (CR) of metastases, 20 after induction treatment and 3 after second‐line chemotherapy, and 16 in partial response (PR). The toxicity of the whole treatment was manageable. The main HDC related‐toxicity was hepatic veno‐occlusive disease grade > 2 occurring in 15% of the patients. The 8‐year EFS of the whole cohort was 34% (95% CI, 22–48%). The 8‐year EFS of the 39 patients who received Bu‐Mel and ASCT was 41% (95% CI, 27–57%). Patients who achieved a CR of metastases at the end of induction chemotherapy had a significantly better outcome than the others (8‐year EFS, 52% vs. 20%; P = 0.02).Conclusions: The long‐term results of this first prospective cohort of patients with metastatic disease treated with the N7 induction chemotherapy and HDC (Bu‐Mel) confirm published data with stable survival curves but with a longer follow‐up. Pediatr Blood Cancer 2014;61:977–981.Keywords
This publication has 19 references indexed in Scilit:
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Event-Free Survival of Patients With High-Risk Neuroblastoma Treated With an N6-Like Induction TreatmentJournal of Clinical Oncology, 2005
- Results of Induction Chemotherapy in Children Older Than 1 Year With a Stage 4 Neuroblastoma Treated With the NB 97 French Society of Pediatric Oncology (SFOP) ProtocolJournal of Clinical Oncology, 2005
- Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk NeuroblastomaJournal of Clinical Oncology, 2004
- High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG‐1) by the European Neuroblastoma Study GroupPediatric Blood & Cancer, 2004
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institutionBone Marrow Transplantation, 1999
- Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow TransplantationAnnals of Internal Medicine, 1998
- Cisplatin ototoxicity in children: A practical grading systemMedical and Pediatric Oncology, 1991